Cyclic dinucleotides for treating conditions associated with STING activity such as cancer

US10723756B2 · kind B2 · utility

Assignee

• Innate Tumor Immunity, Inc. · US

Inventors

• Gary D. Glick · Ann Arbor, US
• Shomir Ghosh · Brookline, US
• Edward J. Olhava · Newton, US
• William R. Roush · West Jupiter, US
• Roger Jones · Llandrindod, GB

Key dates

• Filing date: Jan 11, 2017
• Grant date: Jul 28, 2020
• Expiry date: Jan 11, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or coccrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.